Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  McBeth, Lucien ^a   Grabnar, Maria ^a   Selman, Steven ^a   Hinds, Terry D ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; NEUROPILIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RALOXIFENE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; AR GENE; ARTICLE; BLADDER CANCER; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG TARGETING; ENVIRONMENTAL FACTOR; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GR GENE; HUMAN; INFLAMMATION; LIFESTYLE; OCCUPATIONAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS HAEMATOBIA; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SMOKING; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; URINARY TRACT INFECTION;

EID: 84940434537     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/384860     Document Type: Article

References (122)

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015," CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
2. H. W. Herr, D. M. Schwalb, Z.-F. Zhang et al., "Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial," Journal of Clinical Oncology, vol. 13, no. 6, pp. 1404-1408, 1995.
3. K. D. Sievert, B. Amend, U. Nagele et al., "Economic aspects of bladder cancer: what are the benefits and costs" World Journal of Urology, vol. 27, no. 3, pp. 295-300, 2009.
4. K. Chamie, M. S. Litwin, J. C. Bassett et al., "Recurrence of highrisk bladder cancer: a population-based analysis," Cancer, vol. 119, no. 17, pp. 3219-3227, 2013.
5. M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi, "Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence," Clinical Cancer Research, vol. 9, no. 13, pp. 4653-4665, 2003.
6. M. Okamoto, K. Kawai, C. A. Reznikoff, and R. Oyasu, "Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide," Cancer Research, vol. 56, no. 20, pp. 4649-4653, 1996.
7. J. C. Webster, R. H. Oakley, C.M. Jewell, and J. A. Cidlowski, "Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative isoform: a mechanism for the generation of glucocorticoid resistance," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6865-6870, 2001.
8. M. Ligr, Y. Li, S. K. Logan et al., "Mifepristone inhibits GRbeta coupled prostate cancer cell proliferation," Journal of Urology, vol. 188, no. 3, pp. 981-988, 2012.
9. A. W. Cheever, "Schistosomiasis and neoplasia," Journal of the National Cancer Institute, vol. 61, no. 1, pp. 13-18, 1978.
10. J.D.Christie, D. Crouse, A. S. Kelada, E. Anis-Ishak, J.H. Smith, and I. A. Kamel, "Patterns of Schistosoma haematobium egg distribution in the human lower urinary tract. III. Cancerous lower urinary tracts,"TheAmericanJournal of TropicalMedicine and Hygiene, vol. 35, no. 4, pp. 759-764, 1986.
11. A. W. Cheever, R. E. Kuntz, J. A. Moore, and T.-C. Huang, "Pathology of Schistosoma haematobium infection in the capuchin monkey (Cebus apella)," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 82, no. 1, pp. 107-111, 1988.
12. M. N. El-Bolkainy, N. M. Mokhtar, M. A. Ghoneim, and M. H. Hussein, "The impact of schistosomiasis on the pathology of bladder carcinoma," Cancer, vol. 48,no. 12, pp. 2643-2648, 1981.
13. H. M. Khaled, M. S. Aly, and I. T. Magrath, "Loss of Y chromosome in Bilharzial bladder cancer," Cancer Genetics and Cytogenetics, vol. 117, no. 1, pp. 32-36, 2000.
14. M. P. A. Zeegers, F. E. S. Tan, E. Dorant, and P. A. van den Brandt, "The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies," Cancer, vol. 89, no. 3, pp. 630-639, 2000.
15. S. H. Vermeulen, N. Hanum, A. J. Grotenhuis et al., "Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study," British Journal of Cancer, vol. 112, no. 3, pp. 594-600, 2015.
16. IARC Working Group, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 94 of Ingested Nitrate and Nitrite and Cyanobacterial Peptide Toxins, International Agency for Research on Cancer (IARC), Paris, France, 2010.
17. P. Boffetta, N. Jourenkova, and P. Gustavsson, "Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons," Cancer Causes and Control, vol. 8, no. 3, pp. 444-472, 1997.
18. T. E. Arbuckle, "Are there sex and gender differences in acute exposure to chemicals in the same setting" Environmental Research, vol. 101, no. 2, pp. 195-204, 2006.
19. C. K. Batista, G. Brito, M. Souza, B. Leitaõ, F. Cunha, and R. Ribeiro, "A model of hemorrhagic cystitis induced with acrolein in mice," Brazilian Journal of Medical and Biological Research, vol. 39, no. 11, pp. 1475-1481, 2006.
20. H. Kiuchi, T. Takao, K. Yamamoto et al., "Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation," Journal of Urology, vol. 181, no. 5, pp. 2339-2348, 2009.
21. B. F. Hales, S. Smith, and B. Robaire, "Cyclophosphamide in the seminal fluid of treated males: transmission to females by mating and effect on pregnancy outcome," Toxicology and Applied Pharmacology, vol. 84, no. 3, pp. 423-430, 1986.
22. J. M. Trasler, B. F. Hales, and B. Robaire, "Chronic low dose cyclophosphamide treatment of adult male rats: effect on fertility, pregnancy outcome and progeny," Biology of Reproduction, vol. 34, no. 2, pp. 275-283, 1986.
23. M. Tubiana, "The report of the French Academy of Science: 'problems associated with the effects of low doses of ionising radiation'," Journal of Radiological Protection, vol. 18, no. 4, pp. 243-248, 1998.
24. J. E. Trosko, "Role of low-level ionizing radiation in multi-step carcinogenic process," Health Physics, vol. 70,no. 6, pp. 812-822, 1996.
25. E. Cardis, E. S. Gilbert, L. Carpenter et al., "Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries," Radiation Research, vol. 142, no. 2, pp. 117-132, 1995.
26. J. D. Boice Jr., G. Engholm, R. A. Kleinerman et al., "Radiation dose and second cancer risk in patients treated for cancer of the cervix," Radiation Research, vol. 116, no. 1, pp. 3-55, 1988.
27. A. Morales, D. Eidinger, and A. W. Bruce, "Intracavitary Bacillus CalmetteGuerin in the treatment of superficial bladder tumors," Journal of Urology, vol. 116, no. 2, pp. 180-183, 1976.
28. R. De Jager, E. Guinan, D. Lamm et al., "Long-term complete remission in bladder carcinoma in situ with intravesical tice bacillus Calmette guerin. Overview analysis of six phase II clinical trials," Urology, vol. 38, no. 6, pp. 507-513, 1991.
29. M. S. Cookson and M. F. Sarosdy, "Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy," The Journal of Urology, vol. 148, no. 3, pp. 797-801, 1992.
30. R. Kapoor, V. Vijjan, and P. Singh, "Bacillus Calmette-Guerin in the management of superficial bladder cancer," Indian Journal of Urology, vol. 24, no. 1, pp. 72-76, 2008.
31. N. Ikeda, I. Toida, A. Iwasaki, K. Kawai, and H. Akaza, "Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Gurin (BCG): a role of BCG internalization into tumor cells," International Journal of Urology, vol. 9, no. 1, pp. 29-35, 2002.
32. J.A. Witjes, "Management of BCGfailures in superficial bladder cancer: a review," European Urology, vol. 49, no. 5, pp. 790-797, 2006.
33. J. Baniel, Z. Lev, D. Engelstein, and C. Servadio, "Penile edema andmeatal ulceration after intravesical instillation with Bacillus Calmette-Gurin," Urology, vol. 47, no. 6, pp. 932-934, 1996.
34. V. Demers and V. Pelsser, "'BCGitis': a rare case of tuberculous epididymo-orchitis following intravesical bacillus Calmette-Guerin therapy," Journal of Radiology Case Reports, vol. 6, no. 11, pp. 16-21, 2012.
35. M. Muttarak, B. Lojanapiwat, B. Chaiwun, and S. Wudhikarn, "Preoperative diagnosis of bilateral tuberculous epididymoorchitis following intravesical Bacillus Calmette-Guerin therapy for superficial bladder carcinoma," Australasian Radiology, vol. 46, no. 2, pp. 183-185, 2002.
36. M. Garg, S. N. Sankhwar, A. Goel et al., "Effect of intravesical immunotherapy on sperm parameters in young patients with non-muscle-invasive bladder carcinoma: prospective analysis," Clinical Genitourinary Cancer, vol. 12, no. 3, pp. e83-e86, 2014.
37. R. K. Naz and G. P. Talwar, "Immunological sterilization ofmale dogs by BCG," International Journal of Andrology, vol. 4, no. 1, pp. 111-128, 1981.
38. S. Edin, M. L. Wikberg, A. M. Dahlin et al., "The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer," PLoS ONE, vol. 7, no. 10, Article IDe47045, 2012.
39. G. Gakis, "The role of inflammation in bladder cancer," Advances in Experimental Medicine and Biology, vol. 816, pp. 183-196, 2014.
40. Z. Zhu, Z. Shen, and C. Xu, "Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer,"Mediators of Inflammation, vol. 2012,Article ID528690, 11 pages, 2012.
41. N. Said, H. F. Frierson, M. Sanchez-Carbayo, R. A. Brekken, and D. Theodorescu, "Loss of SPARC in bladder cancer enhances carcinogenesis and progression,"The Journal of Clinical Investigation, vol. 123, no. 2, pp. 751-766, 2013.
42. F. Ajili, N. Kourda, A. Darouiche, M. Chebil, and S. Boubaker, "Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by bcg immunotherapy," Ultrastructural Pathology, vol. 37, no. 1, pp. 56-61, 2013.
43. M. Dufresne, G. Dumas, . Asselin, C. Carrier, M. Pouliot, and C. Reyes-Moreno, "Pro-inflammatory type-1 and antiinflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells," Molecular Immunology, vol. 48, no. 12-13, pp. 1556-1567, 2011.
44. H. Chen, W. Yong, T. D. Hinds Jr. et al., "Fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis," The Journal of Biological Chemistry, vol. 285, no. 36, pp. 27776-27784, 2010.
45. A. Enkelmann, J. Heinzelmann, F. Von Eggeling et al., "Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer," Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5, pp. 751-759, 2011.
46. H. T. Niu, C. M. Yang, G. Jiang et al., "Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery," Journal of Cancer Research and Clinical Oncology, vol. 137, no. 8, pp. 1273-1282, 2011.
47. J. E. Castelao, J.-M. Yuan, M. Gago-Dominguez, M. C. Yu, and R. K. Ross, "Non-steroidal anti-inflammatory drugs and bladder cancer prevention," British Journal of Cancer, vol. 82, no. 7, pp. 1364-1369, 2000.
48. R. D. Klein, C. S. van Pelt, A. L. Sabichi et al., "Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression," Cancer Research, vol. 65, no. 5, pp. 1808-1813, 2005.
49. S. F. Shariat, J.-H. Kim, G. E. Ayala, K. Kho, T. M. Wheeler, and S. P. Lerner, "Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder," Journal of Urology, vol. 169, no. 3, pp. 938-942, 2003.
50. P. J. Bostrm, V. Aaltonen, K.-O. Sderstrm, P. Uotila, and M. Laato, "Expression of cyclooxygenase-1 and-2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells," Pathology, vol. 33, no. 4, pp. 469-474, 2001.
51. W. Lim, C. Park, M. K. Shim, Y. H. Lee, Y. M. Lee, and Y. Lee, "Glucocorticoids suppress hypoxia-induced COX-2 and hypoxia inducible factor-1 expression through the induction of glucocorticoid-induced leucine zipper," British Journal of Pharmacology, vol. 171, no. 3, pp. 735-745, 2014.
52. B. J. Deroo and T. K. Archer,"Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin," Molecular Biology of the Cell, vol. 12, no. 11, pp. 3365-3374, 2001.
53. G. P. Chrousos and T. Kino, "Intracellular glucocorticoid signaling: a formerly simple system turns stochastic," Science's STKE, vol. 2005, no. 304, p. pe48, 2005.
54. L. J. Lewis-Tuffin and J.A. Cidlowski, "Thephysiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance," Annals of the New York Academy of Sciences, vol. 1069, pp. 1-9, 2006.
55. T.D. Hinds Jr., S. Ramakrishnan, H. A. Cash et al., "Discovery of glucocorticoid receptor-beta in micewith a role in metabolism," Molecular Endocrinology, vol. 24, no. 9, pp. 1715-1727, 2010.
56. L. A. Stechschulte, L. Wuescher, J. S. Marino, J. W. Hill, C. Eng, and T. D. Hinds Jr., "Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of pten," The Journal of Biological Chemistry, vol. 289, no. 25, pp. 17885-17894, 2014.
57. J. R. Tata, "Signalling through nuclear receptors," Nature Reviews Molecular Cell Biology, vol. 3, no. 9, pp. 702-710, 2002.
58. R. Kumar, B.H. Johnson, and E. B. Thompson, "Overviewof the structural basis for transcription regulation by nuclear hormone receptors," Essays in Biochemistry, vol. 40, pp. 27-39, 2004.
59. I. Rogatsky, J. M. Trowbridge, andM. J. Garabedian, "Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms," Molecular and Cellular Biology, vol. 17, no. 6, pp. 3181-3193, 1997.
60. A. Yemelyanov, J. Czwornog, D. Chebotaev et al., "Tumor suppressor activity of glucocorticoid receptor in the prostate," Oncogene, vol. 26, no. 13, pp. 1885-1896, 2007.
61. Z. Ni, J. Tang, Z. Cai et al., "A new pathway of glucocorticoid action for asthma treatment through the regulation of PTEN expression," Respiratory Research, vol. 12, article 47, 2011.
62. C. M. Bamberger, A.-M. Bamberger, M. De Castro, and G. P. Chrousos, "Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans," The Journal of Clinical Investigation, vol. 95, no. 6, pp. 2435-2441, 1995.
63. D. Y. M. Leung, Q. Hamid, A. Vottero et al., "Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor ," Journal of Experimental Medicine, vol. 186, no. 9, pp. 1567-1574, 1997.
64. R. H. Oakley, C. M. Jewell, M. R. Yudt, D. M. Bofetiado, and J. A. Cidlowski, "The dominant negative activity of the human glucocorticoid receptor isoform. Specificity and mechanisms of action,"The Journal of Biological Chemistry, vol. 274, no. 39, pp. 27857-27866, 1999.
65. Y. Yin, X. Zhang, Z. Li et al., "Glucocorticoid receptor regulates injury-mediated astrocyte activation and contributes to glioma pathogenesis via modulation of-catenin/TCF transcriptional activity," Neurobiology of Disease, vol. 59, pp. 165-176, 2013.
66. D. Y. M. Leung, M. De Castro, S. J. Szefler, and G. P. Chrousos, "Mechanisms of glucocorticoid-resistant asthma," Annals of the New York Academy of Sciences, vol. 840, pp. 735-746, 1998.
67. C.A. Longui, A. Vottero, P. Adamsonet al., "Lowglucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia," Hormone and Metabolic Research, vol. 32, no. 10, pp. 401-406, 2000.
68. X. Zhang, C.M. Ognibene, A. F. Clark, and T. Yorio, "Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta," Experimental Eye Research, vol. 84, no. 2, pp. 275-284, 2007.
69. Y. C. Zheng, K. Izumi, Y. Li, H. Ishiguro, and H. Miyamoto, "Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals,"Molecular CancerTherapeutics, vol. 11, no. 12, pp. 2621-2632, 2012.
70. H. Ishiguro, T. Kawahara, Y. Zheng, G. J. Netto, and H. Miyamoto, "Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression," The American Journal of Clinical Pathology, vol. 142, no. 2, pp. 157-164, 2014.
71. K. Dietrich, A. Schned, J. Fortuny et al., "Glucocorticoid therapy and risk of bladder cancer," British Journal of Cancer, vol. 101, no. 8, pp. 1316-1320, 2009.
72. Y. Zheng, K. Izumi, Y. Li, H. Ishiguro, and H. Miyamoto, "Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals,"Molecular CancerTherapeutics, vol. 11, no. 12, pp. 2621-2632, 2012.
73. H. Ishiguro, T. Kawahara, Y. Zheng, E. Kashiwagi, Y. Li, and H. Miyamoto, "Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity," Cancer Chemotherapy and Pharmacology, vol. 74, no. 2, pp. 249-255, 2014.
74. N. A. T. M. Huizenga, P. De Lange, J. W. Koper et al., "Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene," Journal of Clinical Endocrinology andMetabolism, vol. 85, no. 5, pp. 2076-2081, 2000.
75. G. Schlossmacher, A. Stevens, and A. White, "Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells," Journal of Endocrinology, vol. 211,no. 1, pp. 17-25, 2011.
76. C. Zhang, J. Mattern, A. Haferkamp et al., "Corticosteroidinduced chemotherapy resistance in urological cancers," Cancer Biology andTherapy, vol. 5, no. 1, pp. 59-64, 2006.
77. Y. Niu, S. Altuwaijri, S. Yeh et al., "Targeting the stromal androgen receptor in primary prostate tumors at earlier stages," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12188-12193, 2008.
78. G. Gakis, A. Stenzl, and M. Renninger, "Evolution of the concept of androgen-sensitive bladder cancer," Scandinavian Journal of Urology, vol. 47, no. 3, pp. 173-178, 2013.
79. I. Lucca, H. Fajkovic, and T. Klatte, "Sex steroids and gender differences in nonmuscle invasive bladder cancer," Current Opinion in Urology, vol. 24, no. 5, pp. 500-505, 2014.
80. C. A. Heinlein and C. Chang, "Androgen receptor in prostate cancer," Endocrine Reviews, vol. 25, no. 2, pp. 276-308, 2004.
81. H. Miyamoto, E. M. Messing, and C. Chang, "Androgen deprivation therapy for prostate cancer: current status and future prospects," Prostate, vol. 61, no. 4, pp. 332-353, 2004.
82. M. Rahman, H. Miyamoto, and C. Chang, "Androgen receptor coregulators in prostate cancer:mechanisms and clinical implications," Clinical Cancer Research, vol. 10, no. 7, pp. 2208-2219, 2004.
83. S. Yeh, H.-C. Chang, H. Miyamoto et al., "Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators," Keio Journal of Medicine, vol. 48, no. 2, pp. 87-92, 1999.
84. J. D. Chen, "Steroid/nuclear receptor coactivators," Vitamins and Hormones, vol. 58, pp. 391-448, 2000.
85. F. Chen, P. Langenstroer, G. Zhang, Y. Iwamoto, and W. A. See, "Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines," Journal of Urology, vol. 170, no. 5, pp. 2009-2013, 2003.
86. H. Miyamoto, Z. Yang, Y.-T. Chen et al., "Promotion of bladder cancer development and progression by androgen receptor signals," Journal of the National Cancer Institute, vol. 99, no. 7, pp. 558-568, 2007.
87. A. M. Johnson, M. J. O'Connell, H. Miyamoto et al., "Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1," BMC Urology, vol. 8, article 7, 2008.
88. S. A. Boorjian, H. V. Heemers, I. Frank et al., "Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder," Endocrine-Related Cancer, vol. 16,no. 1, pp. 123-137, 2009.
89. E. C. Kauffman, B. D. Robinson, M. J. Downes et al., "Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer," Molecular Carcinogenesis, vol. 50, no. 12, pp. 931-944, 2011.
90. B. A. Rosenzweig, P. S. Bolina, L. Birch, C. Moran, I.Marcovici, and G. S. Prins, "Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit," Neurourology and Urodynamics, vol. 14, no. 1, pp. 87-96, 1995.
91. G. Pelletier, "Localization of androgen and estrogen receptors in rat and primate tissues," Histology and Histopathology, vol. 15, no. 4, pp. 1261-1270, 2000.
92. C. M. Wilson and M. J. McPhaul, "A and B forms of the androgen receptor are expressed in a variety of human tissues," Molecular and Cellular Endocrinology, vol. 120, no. 1, pp. 51-57, 1996.
93. S. Salmi, R. Santti, J.-A. Gustafsson, and S. Mkel, "Colocalization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat," Journal of Urology, vol. 166, no. 2, pp. 674-677, 2001.
94. S. Celayir, Z. Ilc, and S. Dervisoglu, "The sex hormone receptors in the bladder in childhood-I: preliminary report in male subjects," European Journal of Pediatric Surgery, vol. 12,no. 5, pp. 312-317, 2002.
95. H. J. Litman, S. Bhasin, M. P. O'Leary, C. L. Link, and J. B. McKinlay, "An investigation of the relationship between sexsteroid levels and urological symptoms: results fromthe Boston Area Community Health survey," BJU International, vol. 100, no. 2, pp. 321-326, 2007.
96. Y. Zheng, K. Izumi, J. L. Yao, and H. Miyamoto, "Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells," Endocrine-Related Cancer, vol. 18, no. 4, pp. 451-464, 2011.
97. L. Cheng, G. T. MacLennan, C. X. Pan et al., "Allelic loss of the active X chromosome during bladder carcinogenesis," Archives of Pathology & LaboratoryMedicine, vol. 128, no. 2, pp. 187-190, 2004.
98. L. M. Reid, I. Leav, and P. W. L. Kwan, "Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R 198) in athymic nude mice," Cancer Research, vol. 44, no. 10, pp. 4560-4573, 1984.
99. J.-W. Hsu, I. Hsu, D. Xu et al., "Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor," American Journal of Pathology, vol. 182, no. 5, pp. 1811-1820, 2013.
100. S. Boorjian, S. Ugras, N. P. Mongan et al., "Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer," Urology, vol. 64, no. 2, pp. 383-388, 2004.
101. W. Tan, S. Boorjian, P. Advani et al., "The estrogen pathway: estrogen receptor-, progesterone receptor, and estrogen receptor-expression in radical cystectomy urothelial cell carcinoma specimens," Clinical Genitourinary Cancer, 2015.
102. S. S. Shen, C. L. Smith, J.-T. Hsieh et al., "Expression of estrogen receptors-and-in bladder cancer cell lines and human bladder tumor tissue," Cancer, vol. 106, no. 12, pp. 2610-2616, 2006.
103. H. T. Kim, B. C. Kim, I. Y. Kimet al., "Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells," The Journal of Biological Chemistry, vol. 277, no. 36, pp. 32510-32515, 2002.
104. S. Karmakar, Y. Jin, and A. K. Nagaich, "Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and activator protein 1 (AP1) in dexamethasone-mediated interference of ERalpha activity,"The Journal of Biological Chemistry, vol. 288, no. 33, pp. 24020-24034, 2013.
105. M.-J. Tsai and B.W.O'Malley, "Molecularmechanisms of action of steroid/thyroid receptor superfamily members," Annual Review of Biochemistry, vol. 63, pp. 451-486, 1994.
106. A. O. Brinkmann and J. Trapman, "Prostate cancer schemes for androgen escape," Nature Medicine, vol. 6, no. 6, pp. 628-629, 2000.
107. A. O. Brinkmann, "Molecular basis of androgen insensitivity," Molecular and Cellular Endocrinology, vol. 179, no. 1-2, pp. 105-109, 2001.
108. J. T. Isaacs andW. B. Isaacs, "Androgen receptor outwits prostate cancer drugs," Nature Medicine, vol. 10, no. 1, pp. 26-27, 2004.
109. G. N. Brooke and C. L. Bevan, "The role of androgen receptor mutations in prostate cancer progression," Current Genomics, vol. 10, no. 1, pp. 18-25, 2009.
110. P. Gupta, M. Jain, R. Kapoor, K. Muruganandham, A. Srivastava, and A. Mandhani, "Impact of age and gender on the clinicopathological characteristics of bladder cancer," Indian Journal of Urology, vol. 25, no. 2, pp. 207-210, 2009.
111. Y. Jing, D. Cui, W. Guo et al., "Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelialmesenchymal transition," Cancer Letters, vol. 348, no. 1-2, pp. 135-145, 2014.
112. W. Jitao, H. Jinchen, L. Qingzuo et al., "Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition," Andrologia, vol. 46, no. 10, pp. 1128-1133, 2014.
113. N. Ferrara, K. Carver-Moore, H. Chen et al., "Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene," Nature, vol. 380, no. 6573, pp. 439-442, 1996.
114. D. R. Bielenberg, C. A. Pettaway, S. Takashima, and M. Klagsbrun, "Neuropilins in neoplasms: expression, regulation, and function," Experimental Cell Research, vol. 312, no. 5, pp. 584-593, 2006.
115. J. R. L. Wild, C. A. Staton, K. Chapple, and B. M. Corfe, "Neuropilins: expression and roles in the epithelium," International Journal of Experimental Pathology, vol. 93, no. 2, pp. 81-103, 2012.
116. A. M. Jubb, L. A. Strickland, S. D. Liu, J. Mak, M. Schmidt, and H. Koeppen, "Neuropilin-1 expression in cancer and development," Journal of Pathology, vol. 226, no. 1, pp. 50-60, 2012.
117. A. M. Jubb, S.M. Sa, N. Ratti et al., "Neuropilin-2 expression in cancer," Histopathology, vol. 61, no. 3, pp. 340-349, 2012.
118. M. R. Saban, T. J. Sferra, C. A. Davis et al., "Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment," The American Journal of Physiology-Renal Physiology, vol. 299, no. 6, pp. F1245-F1256, 2010.
119. W. D. Stamer, E. A. Hoffman, J. M. Luther, D. L. Hachey, and K. L. Schey, "Protein profile of exosomes from trabecular meshwork cells," Journal of Proteomics, vol. 74, no. 6, pp. 796-804, 2011.
120. P. Mirabelli, B. B. Peebo, M. Xeroudaki, M. Koulikovska, and N. Lagali, "Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularizationmodel," Experimental Eye Research, vol. 125, pp. 118-127, 2014.
121. K. Eisermann, C. J. Broderick, A. Bazarov, M. M. Moazam, and G. C. Fraizer, "Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site," Molecular Cancer, vol. 12, article 7, 2013.
122. A. Gericke, M. Munson, and A. H. Ross, "Regulation of the PTEN phosphatase," Gene, vol. 374, no. 1-2, pp. 1-9, 2006.